{
    "clinical_study": {
        "@rank": "164667", 
        "arm_group": [
            {
                "arm_group_label": "Nasaleze", 
                "arm_group_type": "Active Comparator", 
                "description": "Nasaleze 1 puff via \"spray device\" in each nostril 3 times daily for 1 week"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 1 puff via \"spray device\" in each nostril 3 times daily for 1 week"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this protocol are:\n\n        1. to confirm the inhibitory effect of Nasaleze on the immediate  response to nasal\n           challenge with antigen, and\n\n        2. to show that inhibition of the immediate response to nasal challenge with antigen by\n           Nasaleze inhibits subsequent inflammatory events."
        }, 
        "brief_title": "Effect of Nasaleze on Nasal Challenge With Allergen", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Males and females between 18 and 45 years of age.\n\n          2. History of grass and/or ragweed allergic rhinitis.\n\n          3. Positive skin test to grass and/or ragweed antigen.\n\n          4. Positive response to screening nasal challenge.\n\n        Exclusion Criteria:\n\n          1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.\n\n          2. Pregnant or lactating women.\n\n          3. Upper respiratory infection within 14 days of study start.\n\n          4. FEV1<80% of predicted at screening for subjects with history of mild asthma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723397", 
            "org_study_id": "12-1252"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nasaleze", 
                "intervention_name": "Nasaleze  Spray device", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 27, 2013", 
        "location": {
            "contact": {
                "email": "mdetineo@surgery.bsd.uchicago.edu", 
                "last_name": "Marcy deTineo, BSN", 
                "phone": "773-702-5889"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637"
                }, 
                "name": "University of Chicago"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Nasaleze on the Early Reaction to Nasal Challenge With Allergen", 
        "overall_contact": {
            "email": "jlane@surgery.bsd.uchicago.edu", 
            "last_name": "James Lane, BS", 
            "phone": "773-702-5889"
        }, 
        "overall_contact_backup": {
            "email": "mdetineo@surgery.bsd.uchicago.edu", 
            "last_name": "Marcy deTineo, BSN", 
            "phone": "773-702-5889"
        }, 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "Robert M Naclerio, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The difference in change in total nasal symptoms after the antigen challenges on the second day", 
            "measure": "Total nasal symptoms", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723397"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "Nasaleze", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}